New cytokine targets in inflammatory rheumatic diseases

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 5, 2006, Pages 865-878

  Connell, Laura ^b   McInnes, Iain B ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NONE

Author keywords

biological therapy; cytokine; lymphocyte; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AMG 714; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 15; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PRALNACASAN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICULAR CARTILAGE; BIOLOGICAL THERAPY; BONE; CLINICAL TRIAL; COMORBIDITY; DISEASE CONTROL; DRUG BIOAVAILABILITY; DRUG MECHANISM; HEALTH CARE NEED; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFLAMMATION; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR BLOCKING; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TISSUE INJURY; TISSUE REPAIR;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS; CYTOKINES; HUMANS; INTERLEUKIN-12; INTERLEUKIN-15; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-6; INTERLEUKINS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748497103     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.05.011     Document Type: Review

References (58)

1. Taylor P.C., Williams R.O., and Maini R.N. Immunotherapy for rheumatoid arthritis. Current Opinion in Immunology 13 (2001) 611-616
2. Gu Y., Kuida K., Tsutsui H., et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275 5297 (1997) 206-209
3. Ghayur T., Banerjee S., Hugunin M., et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386 (1997) 619-623
4. Torigoe K., Ushio S., Okura T., et al. Purification and characterization of the human interleukin-18 receptor. The Journal of Biological Chemistry 272 (1997) 25737-25742
5. Gracie J.A., Robertson S.E., and McInnes I.B. Interleukin-18. Journal of Leukocyte Biology 73 2 (2003) 213-224
6. Matsui K., Yoshimoto T., Tsutsui H., et al. Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. Journal of Immunology (Baltimore, Md.: 1950) 159 1 (1997) 97-106
7. Stoll S., Jonuleit H., Schmitt E., et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. European Journal of Immunology 28 10 (1998) 3231-3239
8. Pizarro T.T., Michie M.H., Bentz M., et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. Journal of Immunology (Baltimore, Md.: 1950) 162 11 (1999) 6829-6835
9. Prinz M., and Hanisch U.K. Murine microglial cells produce and respond to interleukin-18. Journal of Neurochemistry 72 5 (1999) 2215-2218
10. Conti B., Jahng J.W., Tinti C., et al. Induction of interferon-gamma inducing factor in the adrenal cortex. The Journal of Biological Chemistry 272 4 (1997) 2035-2037
11. Stoll S., Muller G., Kurimoto M., et al. Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. Journal of Immunology (Baltimore, Md.: 1950) 159 1 (1997) 298-302
12. Dao T., Mehal W., and Crispe I.N. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. Journal of Immunology (Baltimore, Md.: 1950) 161 (1998) 2217-2222
13. Micallef M.J., Ohtsuki T., Kohno K., et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. European Journal of Immunology 26 7 (1996) 1647-1651
14. Okamura H., Tsutsi H., Komatsu T., et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378 (1995) 88-91
15. Gutzmer R., Langer K., Mommert S., et al. Human dendritic cells express the IL-18R and are chemoattracted to IL-18. Journal of Immunology (Baltimore, Md.: 1950) 171 12 (2003) 6363-6371
16. Wittmann M., Purwar R., Hartmann C., et al. Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. The Journal of Investigative Dermatology 124 6 (2005) 1225-1233
17. Rooney T., Murphy E., Benito M., et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Annals of the Rheumatic Diseases 63 11 (2004) 1393-1398
18. Wei X.Q., Leung B., Arthur H.M., et al. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. Journal of Immunology (Baltimore, Md.: 1950) 166 1 (2001) 517-521
19. Plater-Zyberk C., Joosten L.A., Helsen M.M., et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. The Journal of Clinical Investigation 108 12 (2001) 1825-1832
20. Nishimoto N., and Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Current Opinion in Pharmacology 4 (2004) 386-391
21. Naka T., Nishimoto N., and Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Research 4 supplement 3 (2002) S233-S242
22. Butler D., Maini R.N., Feldmann M., and Brennan F.M. Blockade of TNFα with chimeric anti TNFα monoclonal antibody, cA2 reduces (IL-6 and IL-8) release in RA NMC cultures: a comparison with IL-1ra. European Cytokine Network 6 (1995) 225-230
23. Alonzi T., Fattori E., Lazzaro D., et al. Interleukin 6 is required for the development of collagen-induced arthritis. The Journal of Experimental Medicine 187 4 (1998) 461-468
24. Takagi N., Mihara M., Moriya Y., et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis and Rheumatism 41 (1998) 2117-2121
25. Choy E.H.S., Isenberg D.A., Garrood T., et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis and Rheumatism 46 (2002) 3143-3150
26. Nishimoto N., Yoshizaki K., Miyasaka N., et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis and Rheumatism 50 (2004) 1761-1769
27. Morita Y., Yamamura M., Nishida K., et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis and Rheumatism 41 (1998) 306-314
28. Hunter C. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nature Reviews Immunology 5 7 (2005) 521-531
29. Trinchieri G., Pflanz S., and Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19 5 (2003) 641-644
30. Hess H., Gately M., Rude E., et al. High doses of interleukin-12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant. European Journal of Immunology 26 (1996) 187-191
31. Malfait A.M., Butler D.M., Presky D.H., et al. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clinical and Experimental Immunology 111 (1998) 377-383
32. Joosten L.A., Lubberts E., Helsen M.M., and van den Berg W.B. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. Journal of Immunology (Baltimore, Md.: 1950) 159 (1997) 4094-4102
33. Finnegan A., Grusby M., Kaplan C.D., et al. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. Journal of Immunology (Baltimore, Md.: 1950) 169 (2002) 3345-3352
34. Joosten L.A., Heuvelmans-Jacobs M., Lubberts E., et al. Local interleukin-12 gene transfer promotes conversion of an acute arthritis to a chronic destructive arthritis. Arthritis and Rheumatism 46 (2002) 1379-1389
35. Kauffman C.L., Aria N., Toichi E., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. The Journal of Investigative Dermatology 123 6 (2004) 1037-1044
36. Mannon P.J., Fuss I.J., Mayer L., et al. Anti-interleukin-12 antibody for active Crohn's disease. The New England Journal of Medicine 351 20 (2004) 2069-2079
37. Aggarwal S., Ghilardi N., Xie M.H., et al. Interleukin-23 promotes a distinct T cell activation state characterized by the production of interleukin-17. The Journal of Biological Chemistry 278 (2003) 1910-1914
38. Murphy C.A., Langrish C., Chen Y., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. The Journal of Experimental Medicine 198 (2003) 1951-1957
39. Larousserie F., Pflanz S., Coulomb-L'Hermine A., et al. Expression of IL-27 in human Th1-associated granulomatous diseases. The Journal of Pathology 202 2 (2004) 164-171
40. Villarino A.V., Huang E., and Hunter C.A. Understanding the pro- and anti-inflammatory properties of IL-27. Journal of Immunology (Baltimore, Md.: 1950) 173 2 (2004) 715-720
41. Goldberg R., Wildbaum G., Zohar Y., et al. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. Journal of Immunology (Baltimore, Md.: 1950) 173 2 (2004) 1171-1178
42. Fehinger T.A., Cooper M., and Caligiuri M.A. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine & Growth Factor Reviews 13 (2002) 169-183
43. Waldmann T. Targeting the interleukin-15 system in rheumatoid arthritis. Arthritis and Rheumatism 52 9 (2005) 2585-2588
44. Lodolce J., Burkitt P., Koka R., et al. Interleukin-15 and the regulation of lymphoid homeostasis. Molecular Immunology 39 (2002) 537-544
45. Kurowska M., Rudnicka W., Kontny E., et al. Fibroblast like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-xL and Bcl-2. Journal of Immunology (Baltimore, Md.: 1950) 169 (2002) 1760-1767
46. Dubois S., Mariner J., Waldmann T.A., and Tagaya Y. IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17 (2002) 537-547
47. Becknell B., and Caligiuri M. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Advances in Immunology 86 (2005) 209-239
48. McInnes I.B., and Gracie J.A. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Current Opinion in Pharmacology 4 4 (2004) 392-397
49. Ruchatz H., Leung B., Wei X.Q., et al. Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. Journal of Immunology (Baltimore, Md.: 1950) 160 11 (1998) 5654-5660
50. Baslund B., Tvede N., Danneskiold-Samsoe B., et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis and Rheumatism 52 9 (2005) 2686-2692
51. McInnes I.B., Martin R., Zimmerman-Gorska I., et al. Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis (RA): results from a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism (2004) [abstract]
52. Chabaud M., Durand J., Buchs N., et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis and Rheumatism 42 5 (1999) 963-970
53. Hwang S.Y., and Kim H.Y. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Molecules and Cells 19 2 (2005) 180-184
54. Kolls J.K., and Linden A. Interleukin-17 family members and inflammation. Immunity 21 (2004) 467-476
55. Firestein G.S., and Zvaifler N. How important are T cells in chronic rheumatoid synovitis?: II. T cell-independent mechanisms from beginning to end. Arthritis and Rheumatism 46 2 (2002) 298-308
56. Lubberts E., Koenders M.I., and van den Berg W.B. The role of T cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Research and Therapy 7 (2005) 29-37
57. Kotake S., Udagawa N., Hakoda M., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis and Rheumatism 44 5 (2001) 1003-1012
58. Lubberts E., Koenders M.I., Oppers-Walgreen B., et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis and Rheumatism 50 2 (2004) 650-659